These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18991236)

  • 41. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
    Sevincok L; Topuz A
    J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder.
    Rodriguez CI; Kegeles LS; Flood P; Simpson HB
    J Clin Psychiatry; 2011 Apr; 72(4):567-9. PubMed ID: 21527129
    [No Abstract]   [Full Text] [Related]  

  • 43. Fluvoxamine treatment of obsessive-compulsive disorder.
    Perse TL; Greist JH; Jefferson JW; Rosenfeld R; Dar R
    Am J Psychiatry; 1987 Dec; 144(12):1543-8. PubMed ID: 3120604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
    McDougle CJ; Price LH; Goodman WK; Charney DS; Heninger GR
    J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder.
    Rasmussen SA
    Am J Psychiatry; 1984 Oct; 141(10):1283-5. PubMed ID: 6435460
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study.
    Dursun SM; Deakin JF
    J Psychopharmacol; 2001 Dec; 15(4):297-301. PubMed ID: 11769825
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Topiramate may modulate alcohol abuse but not other compulsive behaviors in frontotemporal dementia: case report.
    Cruz M; Marinho V; Fontenelle LF; Engelhardt E; Laks J
    Cogn Behav Neurol; 2008 Jun; 21(2):104-6. PubMed ID: 18541987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin.
    Eriksson T
    Int Clin Psychopharmacol; 2007 Jan; 22(1):57-61. PubMed ID: 17159461
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Open-label study of duloxetine for the treatment of obsessive-compulsive disorder.
    Dougherty DD; Corse AK; Chou T; Duffy A; Arulpragasam AR; Deckersbach T; Jenike MA; Keuthen NJ
    Int J Neuropsychopharmacol; 2015; 18(2):. PubMed ID: 25637377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neuroprotective effect of memantine combined with topiramate in hypoxic-ischemic brain injury.
    Liu C; Lin N; Wu B; Qiu Y
    Brain Res; 2009 Jul; 1282():173-82. PubMed ID: 19501064
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder.
    Marinova Z; Chuang DM; Fineberg N
    Curr Neuropharmacol; 2017; 15(7):977-995. PubMed ID: 28322166
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication.
    Drapalski AL; Rosse RB; Peebles RR; Schwartz BL; Marvel CL; Deutsch SI
    Clin Neuropharmacol; 2001; 24(5):290-4. PubMed ID: 11586114
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo.
    Jenike MA; Baer L; Summergrad P; Minichiello WE; Holland A; Seymour R
    Am J Psychiatry; 1990 Jul; 147(7):923-8. PubMed ID: 2192564
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Effectiveness and safety of topiramate in treatment-resistant bipolar disorder].
    Vieta E; Gilabert A; Rodríguez A; García-Castrillón A; Luna MJ; Arrufat E; García-Parés G
    Actas Esp Psiquiatr; 2001; 29(3):148-52. PubMed ID: 11412488
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Response of obsessive compulsive disorder to carbamazepine in two patients with comorbid epilepsy.
    Koopowitz LF; Berk M
    Ann Clin Psychiatry; 1997 Sep; 9(3):171-3. PubMed ID: 9339883
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Topiramate in drug-resistant complex partial status epilepticus.
    Reuber M; Evans J; Bamford JM
    Eur J Neurol; 2002 Jan; 9(1):111-2. PubMed ID: 11784388
    [No Abstract]   [Full Text] [Related]  

  • 57. Effects of Rapastinel (Formerly GLYX-13) on Serum Brain-Derived Neurotrophic Factor in Obsessive-Compulsive Disorder.
    Linkovski O; Shen H; Zwerling J; Filippou-Frye M; Jo B; Cordell E; Cooper TB; Simpson HB; Burch RM; Moskal JR; Lee F; Rodriguez CI
    J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29505186
    [No Abstract]   [Full Text] [Related]  

  • 58. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.
    Pittenger C; Bloch MH; Williams K
    Pharmacol Ther; 2011 Dec; 132(3):314-32. PubMed ID: 21963369
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Topiramate for the treatment of post traumatic stress disorder. A case study].
    Aalbersberg CF; Mulder JM
    Tijdschr Psychiatr; 2006; 48(6):487-91. PubMed ID: 16956009
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder.
    Grant P; Song JY; Swedo SE
    J Child Adolesc Psychopharmacol; 2010 Aug; 20(4):309-15. PubMed ID: 20807069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.